Draft CEPAC Supplementary Report of Treatment Options for Attention Deficit Hyperactivity Disorder Posted For Public Comment

Boston, Mass., May 11, 2012 – The Institute for Clinical and Economic Review (ICER) has posted the draft supplementary report “Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-risk Preschoolers & Long-term Effectiveness in All Ages” as a complement to the full report from the Agency for Healthcare Research and Quality (AHRQ). Both reports will be the subject of deliberation and vote at the third public meeting of the New England Comparative Effectiveness Public Advisory Council (CEPAC) on Friday, June 1, 2012 in Durham, New Hampshire. The report prepared for CEPAC includes supplementary analyses to the original AHRQ review, including budget impact and cost-effectiveness analyses.

 

This supplementary report aims to help members of CEPAC, and the public, understand the latest evidence on the relative effectiveness of different management options for patients with attention deficit hyperactivity disorder. The report will be available for public comment until May 22, 2012.

 

Date: Friday, June 1, 2012

Time: 10:00 AM – 4:00 PM ET

Location: The University of New Hampshire

Holloway Commons, 1st floor

Squamscott Room

75 Main Street

Durham, NH 03824

 

Members of the public wishing to attend the meeting must register by May 29, 2012 by visiting the “Contact Us” section of cepac.icer-review.org. The website also includes instructions for those wishing to submit written comments ahead of time, and those requesting the opportunity to make public comments at the meeting. Members of the public unable to attend the meeting in person will be able to observe the meeting via webinar. Log-in instructions will be posted to the CEPAC website one week prior: cepac.icer-review.org.

 

 

The New England Comparative Effectiveness Public Advisory Council (CEPAC) is a regional body whose goal is to provide objective, independent guidance on the application of medical evidence to clinical practice and payer policy decisions across New England. Supported by a federal grant from the Agency for Healthcare Research and Quality (AHRQ), and with backing from a consortium of New England state health policy leaders, CEPAC holds public meetings to consider evidence reviews of medical tests and treatments and provide judgments regarding how the evidence can best be used across New England to improve the quality and value of health care services. CEPAC consists of practicing physicians and methodologists with experience in evaluating and using evidence in the practice of healthcare, as well as patient/public members with experience in health policy, patient advocacy and public health. ICER is managing the day-to-day operations of CEPAC as part of its federally funded RAPiD (Regional Adaptation for Payer Policy Decisions) initiative meant to develop and test new ways to adapt federal evidence reviews to improve their usefulness for patients, clinicians, and payers. A list of CEPAC members, and other information about the project, is available online at cepac.icer-review.org.

 

The Institute for Clinical and Economic Review (ICER), based at the Massachusetts General Hospital’s Institute for Technology Assessment (ITA) and an affiliate of Harvard Medical School, provides independent evaluation of the clinical effectiveness and comparative value of new and emerging technologies. Structured as a fully transparent organization, ICER seeks to achieve its ultimate mission of informing public policy and spurring innovation in the use of evidence to improve the value of health care for all. For more information, please visit www.icer-review.org.

 

###